Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China
Under the Chinese health system, penpulimab plus paclitaxel and carboplatin is cost-effective for metastatic sq-NSCLC patients and can be used as an economical and effective treatment option.
Authors
- Chunyan Yan (ORCID: https://orcid.org/0000-0002-9209-6630)
- Xuechen Huo
- Liangxiao Wang (ORCID: https://orcid.org/0009-0002-1955-9616)
- Yuan Gao (ORCID: https://orcid.org/0000-0001-8610-7981)
- Ruigang Diao (ORCID: https://orcid.org/0000-0001-7946-9140)
- Na Lv (ORCID: https://orcid.org/0000-0003-2095-9780)
Institutions
- Yuhuangding Hospital (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-091650
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04